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Abstract
Background: Health related quality of life measurements are vital elements of public health surveillance that
uncover unmet health needs and predict the success of health interventions. We described health related quality
of life measurements using the EuroQoL 5-dimension (EQ-VAS/EQ-5D) instrument and associated factors among
patients with upper gastrointestinal bleeding (UGIB) and hepatic schistosomiasis at a rural health facility in the Albert
Nile Basin, Uganda.
Methods and materials: This was a cross-sectional study at Pakwach Health Centre IV. Participants included adult
inpatients and outpatients with a history of UGIB and ultrasound evidence of hepatic schistosomiasis. We evaluated
and recorded each participant’s medical history, physical examination, laboratory tests results, ultrasound results, and
endoscopy findings. We also recorded health related quality of life measurements using the EuroQoL 5-dimension
instrument and derived disability weights from EQ-VAS and EQ-5D measurements. These were our dependent variables. Descriptive and inferential statistics were generated summarizing our findings.
Results: We found 103 participants had a history of upper gastrointestinal bleeding and hepatosplenic schistosomiasis. Sixty percent were between the ages of 30–49 years, 59% were females, 74% were farmers, 92% had splenomegaly, 88% had varices at endoscopy, 22% were medical emergencies with acute variceal upper gastrointestinal
bleeding, and 62% had anemia. Measures of the different dimensions of health from 101 participants with patient
reported outcomes revealed 77 (76%) participants experienced problems in self-care, 89 (88%) participants reported
anxiety or depression, and 89 (88%) participants experienced pain or discomfort. The median EQ-VAS derived disability weights and median EQ-5D index-derived disability weights were 0.3 and 0.34, respectively. Acute upper
gastrointestinal bleeding, praziquantel drug treatment, and age by decade predicted higher EQ-VAS derived disability
weights (p value < 0.05). Under weight (Body mass index ≤ 18.5), acute upper gastrointestinal bleeding, ascites, age by
decade, female gender, and praziquantel drug treatment predicted higher EQ-5D index- derived disability weights (p
value < 0.05).
Conclusion: Adult patients with upper gastrointestinal bleeding and hepatic schistosomiasis from this primary
health facility experience poor health and considerable health loss. Several factors predicted increased health loss.
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These factors probably represent key areas of health intervention towards mitigating increased health loss in this
population.
Keywords: Health related quality of life measurements, Disability weights, Upper gastrointestinal bleeding,
Schistosomiasis, EQ-5D/EQ-VAS

Background
Dr. Warren in 1978 termed hepatic schistosomiasis, the
“great neglected disease of the liver”. Hepatic schistosomiasis is an insidious disease that follows embolization of
schistosoma eggs to the liver and portal system, leading
to chronic inflammation, tissue injury, and progressive
tissue fibrosis [1, 2]. Extensive periportal fibrosis, portal
hypertension, varices, upper gastrointestinal bleeding,
splenomegaly, and ascites are the hallmarks of advanced
disease. Variceal upper gastrointestinal bleeding is the
principal cause of morbidity, hospital admissions, and
death among individuals with advanced hepatic schistosomiasis [3–8].
Chronic infection with S. mansoni is the only cause
of hepatic schistosomiasis in Sub-Saharan Africa. In
Uganda, the Albert Nile basin is a hot spot for S. mansoni
infection [9, 10]. Studies show that between 30% to 50%
of persons infected with S. mansoni from the Albert Nile
basin had hepatic schistosomiasis [11–16]. Studies also
show that 20% to 50% of adult patients diagnosed with
hepatic schistosomiasis from an endemic area will also
have portal hypertension, varices, variceal upper gastrointestinal bleeding at the time of first diagnosis [6, 8].
Currently Praziquantel mass drug administration is
the main control intervention for schistosomiasis worldwide. However, current evidence shows that Praziquantel
mass drug administration has failed. Many Countries in
Sub-Saharan Africa, including Uganda, did not meet the
World Health Organization’s goal for control and elimination of schistosomiasis by the year 2020 [17–20].
In Uganda, limited health financing has restricted
schistosomiasis control measures to surveillance and
Praziquantel mass drug administration [21, 22]. As a
result, other aspects of control and care of patients with
hepatic schistosomiasis seem neglected [23, 24]. Nowadays, there is no new data about the morbidity, mortality,
and quality of life of patients with upper gastrointestinal
bleeding and hepatic schistosomiasis from the Albert
Nile basin. It is still not clear what health problems
patients with upper gastrointestinal bleeding and hepatic
schistosomiasis from the Albert Nile Basin face. We also
do not know what perceptions they have about their
health status as they seek healthcare.
Measures of the health status of individuals and populations are essential for any evidence-based health policy.
Health related quality of life measurements are also vital

elements of public health surveillance. Health related
quality of life measurements can uncover unmet health
needs and predict the success of health interventions
[25, 26]. However, patients may experience unmet needs
that based on their clinical profile or on various clinical
factors.
Health related quality of life measurements are important for successful control of hepatic schistosomiasis and
upper gastrointestinal bleeding in the Albert Nile Basin.
While clinical factors associated health related quality of
life measurements are important for identifying unmet
needs in clinical care.
We described health related quality of life measurements using the EQ-5D tool and associated clinical factors among patients with upper gastrointestinal bleeding
and hepatic schistosomiasis at a rural health facility in
the Albert Nile Basin.

Materials and methods
This was a cross-sectional study that involved individuals attending the outpatient department and inpatients
admitted acutely with severe upper gastrointestinal
bleeding at the same health facility. The study was conducted over 6 weeks between the months of July and
August 2014 at Pakwach Health Centre IV, a government
run primary health care facility located on the banks of
the Albert Nile in northwestern Uganda. Pakwach Health
Centre provides outpatient and inpatient health care services to a population who are mainly fisher persons and/
or farmers. Epidemiological data suggests close to 50% of
the populations served by this facility are infected with
S. mansoni despite over a decade of Praziquantel chemotherapy. Medical records from the facility indicated about
120 patients every year are admitted for acute upper
gastrointestinal bleeding as a complication of chronic
schistosomiasis.
Eligibility for study participation included written
informed consent and ascent, all patients ≥ 12 years
of age with a medical history of upper gastrointestinal bleeding (past or current). We excluded pregnant
women, HIV positive individuals, and any participant
unable to have endoscopy for upper gastrointestinal
bleeding. Pregnant women were excluded because of the
restrictions of undertaking endoscopy. HIV patients were
excluded from this study because ethical considerations
(confidentiality and partner disclosure) and the fact that

Opio et al. J Patient Rep Outcomes

(2021) 5:112

another study was already recruiting patients with HIV
and schistosomiasis [7, 27].
Upper gastrointestinal bleeding was defined by any
lifetime history of hematemesis, melena, or hematochezia. Participants at the outpatient’s department were systematically sampled and enrolled, while inpatients were
consecutively recruited over 6 weeks. A detailed medical
history that included socio-demographic data, exposure
to schistosoma species or alcohol, treatment of schistosomiasis and time from the last treatment, history of upper
gastrointestinal bleeding, and other relevant past medical history. Participants were examined for stigmata of
chronic liver disease, and vital signs [7, 27].
Measures of health-related quality of life were obtained
using the three-level European Quality of Life 5-Dimensions (EQ-5D-Y) questionnaire and the visual analogue
scale (EQ-VAS) from the EuroQol Group (EQ-5D™) [28,
29]. The EQ-5D-Y is a multi-attribute utility instrument.
The EQ-5D represents measures of personal well-being
and this indicates opinions referenced to the general
population. It has 5 dimensions that include mobility,
self-care, usual activities, pain/discomfort, and anxiety/
depression. Each dimension is rated as a Likert scale
from having no problems (level 1), some problems (level
2), to extreme problems (level 3). The EQ-5D data was
converted into an index of health (EQ-5D index) using
crosswalk values from Zimbabwe in Stata [30]. These
were considered the closest values to our study population. Zimbabwe is found in south sub-Saharan Africa
and schistosomiasis is endemic in Zimbabwe [31]. The
economic and health indices are comparable. The EQ-5D
index represents a measure of health from 0 for death
to 1 for perfect health. The EQ-VAS is a visual analogue
scale (VAS). The scale varies from 0, the worst imaginable health state, to 100, the best imaginable health state.
The EQ-VAS asks patients to indicate their overall health
on a vertical visual analogue scale (0 to 100). This indicates opinions referenced to an individual. The EQ-VAS
and EQ-5D index were then transformed to disability weights by the formulas [EQVAS-derived disability
weights = 1 − (VAS/100)] and [EQ-5D index-derived disability weights = 1 − EQ-5D index] respectively. A disability weight is a weight factor that reflects the severity of
the disease on a scale from 0 (perfect health) to 1 (equivalent to death). Disability weights characterize the amount
of health loss associated with specific health outcomes
and are used to calculate years living with disability [28,
29, 32–35].
Blood was analyzed generating 3-part hematology
indices (using a compact Sysmex KX-21 hematology
analyzer), hepatitis B and C viral blood serology results
(obtained from commercially available rapid diagnostic
test kits), and malaria antigen test results (from rapid
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diagnostic test kits). Stool microscopy was performed for
Ova and urine for schistosomiasis using the urine circulating cathodic antigen (CCA) test by Rapid Diagnostics.
Trans-abdominal ultrasonography was performed by a
trained sonographer according to the modified World
Health Organization Niamey protocol using the SONOSTAR model SS8, a portable ultrasound with a 3.5 MHz
convex probe. Upper digestive endoscopy was performed
using a Pentax EPKi digital video processor and a Pentax
9.8 mm video gastroscope after a local anesthetic (Xylocaine spray) by a gastroenterologist.
Data was transcribed from questionnaires and entered
to Microsoft Access database. This was edited to ensure
quality and exported to Stata version 16 (STATA Corp,
Lakeway, College Station, Texas, USA).
Descriptive and inferential statistics were generated.
These described the study population and measures of
health-related quality of life (EQ-VAS, EQ-5D dimension, EQ-5D index, EQ-VAS-derived disability weights,
and EQ-5D index-derived disability weights). Clinical factors associated with EQ-VAS-derived disability
weights, and EQ-5D index-derived disability weights
were also explored. Categorical data were summarized
as proportions with logit-transformed 95% confidence
intervals. Continuous data were summarized as medians,
interquartile range (IQR), and 95% confidence intervals.
Medians and their 95% confidence intervals were generated using binomial method that makes no assumptions
about the underlying distribution of the variable.
The strength and direction of relationship between
EQ-5D dimensions, EQ-VAS, EQ-5D index, EQ-VASderived disability weights, and EQ-5D index-derived disability weights were explored by Spearman’s correlation
coefficient. This is summarized in a table format.
Multivariable analysis involved disability weights (EQVAS-derived disability weights and EQ-5D index-derived
disability weights) as the dependent variables. We designated clinical variables highlighted in Table 4 as independent variables. These included the following variables
age range, gender, occupations (farmer and fishermen),
body mass index, ascites, splenomegaly, edema, jaundice,
esophageal varices, acute upper gastrointestinal bleeding, urine CCA for detection of schistosomiasis, hepatitis B surface antigen positivity, and previous treatment
with praziquantel. Lasso in Stata 16 was used to select
covariates and models. This process included cross validation, adaptive lasso, plug in’s for heteroskedasticity
and homoskedasticity. We selected best regression models based on “Goodness of fit” after Lasso. Considering
error variance, we performed heteroskedasticity linear
regression for EQ-VAS-derived disability weights as the
dependent variable. Homoskedasticity linear regression
was performed for EQ-5D index-disability weights as the
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dependent. The models were subject to population averaged marginal effects analysis for all covariates in Stata.
A significance level (p value < 0.05) was considered for all
analysis, and confidence intervals or standard errors supported inference. We summarized these results as text, in
tables, and as figures.
Ethics statement

This was a cross-sectional study that involved human
participants. School of Medicine, Makerere University,
Institutional review board, Kampala, Uganda (#REC
REF2011-244), and the Uganda National Council for
Science and Technology, Kampala, Uganda (UNCST
approval #, HS 1620) approved this study. The study was
conducted according to the principles expressed in the
Declaration of Helsinki. Written informed consent was
obtained from all participants.

Results
All participants had a past or current medical history of
upper gastrointestinal bleeding. One fifth (23 participants
out of 107 enrolled) presented as medical emergencies
and were admitted with acute severe upper gastrointestinal bleeding over the study period. We screened 324
at the outpatient’s department over the same period and
were able to enroll 84 patients with a past medical history
of upper gastrointestinal bleeding.
Four out of the 107 participants did not have any
evidence of hepatic schistosomiasis after ultrasonography. Of 103 participants who had hepatic schistosomiasis, 2 participants had missing EQ-5DY records. The
youngest participant was 25 years and the oldest was
71 years. Sixty percent of our study population were aged
30–49 years. The female-male ratio was 7 to 5. Most participants were long-term residents of Pakwach. All participants had frequent contact with the waters of the Nile
(5–7 times a week) and nearly all were either fisherpersons or farmers by occupation. Among our participants,
55% had a prior diagnosis of intestinal schistosomiasis,
88% had ever received Praziquantel in the past, 8% had
active infection at the time of enrolment, 92% had splenomegaly on physical exam and 96% had moderate to
severe periportal fibrosis and/or cirrhosis at ultrasonography. All reported experiencing upper gastrointestinal
bleeding with 96% reporting at least one lifetime episode
of hematemesis, and 97% reporting past admission for
upper gastrointestinal bleeding. No participant has ever
had an endoscopy for upper gastrointestinal bleeding nor
was on propranolol for prevention of recurrent variceal
bleeding. Endoscopy was performed on all 107 participants during the study. Following endoscopy, we found
86 had varices, 8 had both varices and peptic ulcers, and
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21 had peptic ulcers alone. Among the 103 participants
who had hepatic schistosomiasis, 85 (83%) had varices
and 18 (18%) had peptic ulcer disease. The clinical, laboratory, ultrasound, and endoscopic characteristics of the
103 participants, proportions and their 95% confidence
intervals are summarized in Table 1.
Health related quality of life measurements

Measures of the 5 dimensions of health revealed 77 (76%)
participants had some or extreme problems in self-care,
89 (88%) participants reported some or extreme anxiety
or depression, and 90 (89%) participants reported experiencing some or extreme pain or discomfort. Only 37
(37%) participants reported some or extreme problems in
their mobility. However, 55 (55%) participants were able
to undertake their usual activities without any problems
(Fig. 1).
Table 2 summarizes calculated medians with confidence intervals for the EQ visual analogue scale measurements, EQ-5D utility index, EQ visual analogue
scale derived disability weights, and EQ-5D utility index
derived disability weights by different response variables.
Covariates of interest had a median EQ visual analogue
scale derived disability weight > 0.40 or a median EQ-5D
utility index derived disability weight > 0.35.
Table 3 summarizes spearman’s rank correlation coefficients and significance levels (p value < 0.05) for all the
5 dimensions of the EQ-5D questionnaire, EQ visual
analogue scale, EQ-5D utility index, EQ visual analogue
scale derived disability weights, and EQ-5D utility index
derived disability weights. EQ-5D index was positively
and very strongly correlated with EQ-VAS (Spearman’s
rank correlation, n = 101, Rho = 0.73, p value = 0.0001).
A guide enabling inference of the correlation coefficients’
is provided within the table (interpretation of effect size)
[36]. All parameters showed moderate to very large correlations with each other (0.30 to 0.9).
Averaged marginal effects for all covariates for EQ visual
analogue scale derived disability weights, and EQ‑5D
utility index derived disability weights

Our results demonstrated that the probability of EQVAS derived disability weights increased by 30 percentage points, 15 percentage points, 5 percentage points,
and 7 percentage points when one experienced acute
upper gastrointestinal bleeding, received praziquantel
drug treatment, for every age by decade, and if one were
of female gender respectively. While the probability of
EQ-VAS derived disability weights decreased by 12 percentage points when one had Jaundice. All these changes
were statistically significant (Table 4 and Fig. 2).
We also demonstrated that probability of EQ-5D index
derived disability weights increased by 19 percentage
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Table 1 Clinical, laboratory, ultrasound, and endoscopic characteristics of adult patients with hepatosplenic schistosomiasis and
upper gastrointestinal bleeding
N = 103a

Percentage

Logit confidence limits
Lower limit (5%)

Upper
limit
(95%)

Age ranges
Age = 18–29 years

Age = 30–39 years

Age = 40–49 years

Age = 50–59 years

Age = 60–69 years
Age ≥ 70 years

4

1

10

24

17

34

36

27

46

18

12

27

15

9

23

3

1

9

Gender
Male

41

32

51

Female

59

49

68

Stayed in Pakwach for over 10 years
No

12

7

20

Yes

88

80

93

Contact with the Nile 5 to 7 times a week
No

1

0

7

Yes

99

93

100

Farmer
No

26

19

36

Yes

74

64

81

Fisherman
No

84

76

90

Yes

16

10

24

Hematemesis
No

4

1

10

Yes

96

90

99

Melena stool
No

55

46

65

Yes

45

35

54

Hematochezia
No

49

39

58

Yes

51

42

61

Schistosomiasis by positive stool test in the past
No

45

35

54

Yes

55

46

65

Praziquantel
No

12

7

20

Yes

88

80

93

Ever admitted for upper gastrointestinal bleeding
No

3

1

9

Yes

97

91

99

Ever received a blood transfusion
No

30

22

40

Yes

70

60

78

Splenomegaly

(physical examination)

No

8

4

16

Yes

92

84

96
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Table 1 (continued)
N = 103a

Percentage

Logit confidence limits
Lower limit (5%)

Ascites

Upper
limit
(95%)

(physical examination)

No

83

74

89

Yes

17

11

26

Jaundice

(physical examination)

No

89

82

94

Yes

11

6

18

Edema

(physical examination)

No

88

80

93

Yes

12

7

20

Body mass index
17

10

25

18.5–24.9

≤ 18.5

79

70

86

25–29.9

4

2

11

Acute Severe variceal upper gastrointestinal bleeding
No

78

69

85

Yes

22

15

31

Fibrosis patterns
C

5

2

11

D

33

25

43

E

20

14

29

F

4

1

10

X

38

29

48

Spleen length ≥ 15 cm
No

40

31

50

Yes

60

50

69

Portal vein ≥ 13 mm
No

23

16

33

Yes

77

67

84

No

85

77

91

Yes

15

9

23

< 6.5

19

13

28

6.5–7.9

11

7

20

Ascites at ultrasound

Anemia grade(gm/dl)

8–9.4

15

9

23

9.5–10.9

17

10

25

≥ 11

38

29

48

No

93

86

97

Yes

7

3

14

Hepatitis B surface antigen positive

Hepatitis C antibody positive
No

74

64

81

Yes

26

19

36

No

92

85

96

Yes

8

4

15

Urine CCA

Varices
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Table 1 (continued)
N = 103a

Percentage

Logit confidence limits
Lower limit (5%)

Upper
limit
(95%)

No

17

11

26

Yes

83

74

89

a

Two participants had incomplete EQ5D records from the 103 participants

EQ-5D-3L
No problems
4.95%

Some problems
8.91%

9.90%

Unable/Extreme problems
11.88%

13.86%

76.24%

74.26%

11.88%

11.88%

33.66%
45.54%

66.34%

61.39%
45.54%

23.76%

MOBILITY

SELFCARE

USUAL ACTVITY

PAIN/DISCOMFORT

ANXIETY/ DEPRESSION

Fig.1 Response distribution of EQ5D-3 level domains for participants with upper gastrointestinal bleeding and schistosomiasis (n = 101)

points, 10 percentage points, 19 percentage points, 03
percentage points, 10 percentage points, and 12 percentage points when one was under weight (BMI ≤ 18.5),
experienced acute upper gastrointestinal bleeding, one
had ascites, for every age by decade, if one was of female
gender, and had praziquantel drug treatment respectively.
All these changes were statistically significant. All these
changes were statistically significant (Table 4 and Fig. 3).

Discussion
Our study reports about EQ-5D derived health-related
quality of life measurements from patients with hepatic
schistosomiasis and upper gastrointestinal bleeding at a
rural health facility in the Albert Nile basin. As far as we
know, few studies have published EQ-5D outcome measurements about patients with hepatic schistosomiasis.
One study from Brazil and involved patients with S. mansoni infection [34]. The other study from China involved
patients with S. japonica infection [32]. Our study is
unique because it is from Sub-Saharan Africa, where 90%
of those who have schistosomiasis worldwide reside. It
is also distinct because we focused only on patients with

any life history of upper gastrointestinal bleeding at a
rural primary health care facility in rural Africa. Primary
health care research is essential for improved health policy [37].
The characteristics of our participants are not unique.
Daily contact with the waters of the Nile, periportal
fibrosis, splenomegaly, and varices were frequent in our
study participants. This is in keeping with published
literature [13, 16, 38–40]. The differential diagnosis of
such a clinical profile is liver cirrhosis. However, liver
cirrhosis was less likely because of the low prevalence
of alcohol misuse and viral hepatitis B or C infections
in our study [7]. We also found a low prevalence of stigmata of chronic liver disease including ascites, hepatic
encephalopathy, and jaundice. These stigmata are more
frequent in liver cirrhosis than hepatosplenic schistosomiasis [40, 41]. Peptic ulcer disease was infrequent and
was less likely to cause upper gastrointestinal bleeding among our participants. Regarding care, none of
our participants had endoscopy, and no participant
with varices was on propranolol to prevent recurrent
variceal bleeding before enrollment into the study.
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Table 2 Medians (95% confidence intervals) of EQ-VAS, EQ-5D index, and derived disability weights by different clinical factors
n

All participants

EQ-VAS

101

EQ-5D index

EQ-VAS derived
disability weights

EQ-5D index
derived disability
weights

Median

95% CI

Median

95% CI

Median

95% CI

Median

95% CI

70

60, 70

0.59

0.59, 0.62

0.30

0.30, 0.40

0.34

0.31, 0.35

Age, years
18–29

4

75

70, 90

0.67

0.59, 0.73

0.25

0.10, 0.30

0.26

0.21, 0.35

30–39

25

70

60, 80

0.62

0.52, 0.62

0.30

0.20, 0.40

0.31

0.31, 0.38

40–49

36

65

50, 70

0.62

0.59, 0.62

0.35

0.30, 0.50

0.31

0.31, 0.35

50–59

18

50

40, 80

0.59

0.09, 0.73

0.50

0.20, 0.60

0.38

0.31, 0.53

60–69

15

60

50, 70

0.52

0.19, 0.62

0.40

0.30, 0.50

0.40

0.31, 0.50

≥ 70

Men

3

30

20, 60

40

70

50, 80

− 0.13

0.62

− 0.18, − 0.13

0.59, 0.66

0.70

0.40, 0.80

0.78

0.77, 0.78

0.30

0.20, 0.50

0.31

0.30, 0.35

Women

61

60

50, 70

0.55

0.52, 0.62

0.40

0.30, 0.50

0.36

0.31, 0.40

Fisherman

14

70

50, 80

0.68

0.58, 0.79

0.30

0.20, 0.50

0.33

0.21, 0.42

Farmer

76

70

60, 70

0.65

0.62, 0.70

0.30

0.30, 0.40

0.35

0.31, 0.38

Jaundice
No

90

70

60, 70

0.62

0.59, 0.62

0.30

0.30, 0.40

0.31

0.31, 0.35

Yes

11

60

40, 70

0.52

− 0.16, 0.59

0.40

0.30, 0.60

0.40

0.34, 0.68

Edema
No

90

70

60, 70

0.62

0.59, 0.62

0.30

0.30, 0.40

0.31

0.31, 0.35

Yes

11

40

30, 50

0.15

− 0.18, 0.62

0.60

0.50, 0.70

0.48

0.31, 0.77

Splenomegaly
No

8

65

20, 90

0.57

0.35

0.10, 0.80

0.36

0.17, 0.99

Yes

89

70

60, 70

0.62

0.59, 0.62

0.30

0.30, 0.40

0.32

0.31, 0.35

4

30

10, 40

0.12

− 0.59, 0.15

0.70

0.60, 0.90

0.51

0.48, 1.15

Tense ascites (exam difficult)
Praziquantel

− 0.35, 0.80

No

11

80

70, 90

0.66

0.52, 0.80

0.2

0.10, 0.30

0.30

0.17, 0.34

Yes

90

60

50, 70

0.59

0.52, 0.62

0.4

0.30, 0.50

0.35

0.31, 0.40

Body mass index ≤ 18.5
No

84

70

60, 70

0.62

0.59, 0.62

0.3

0.30, 0.40

0.31

0.31, 0.35

Yes

17

50

40, 70

0.52

1.66, 0.62

0.5

0.30, 0.60

0.41

0.31, 0.78

Liver fibrosis pattern score
C

5

60

50, 90

0.59

D

34

70

60, 80

0.62

− 0.13, 0.70

0.55, 0.66

0.4

0.10, 0.50

0.35

0.21–0.78

0.3

0.20, 0.40

0.31

0.30, 0.35

E

21

70

50, 80

0.62

0.52, 0.62

0.3

0.20, 0.50

0.32

0.31, 0.40

F

3

50

50, 80

0.59

0.52, 0.62

0.5

0.20, 0.50

0.36

0.31, 0.40

X

38

60

50, 70

0.59

0.24, 0.62

0.35

0.31, 0.42

0.35

0.31, 0.42

Ascites by ultrasound
No

87

70

60, 70

0.62

0.59, 0.62

0.3

0.30,0.40

0.31

0.31, 0.35

Yes

14

40

30, 50

0.15

− 1.26, 0.52

0.6

0.50, 0.70

0.48

0.40, 0.77

Varices
No

18

70

50, 80

0.6

0.52, 0.67

0.3

0.20, 0.50

0.33

0.30, 0.40

Yes

83

70

50, 70

0.59

0.52, 0.63

0.3

0.30, 0.50

0.35

0.31, 0.36

Acute upper gastrointestinal bleeding
No

79

70

70, 80

0.62

0.59, 0.62

0.3

0.20, 0.30

0.31

0.31, 0.35

Yes

22

40

30, 50

0.2

− 0.13, 0.59

0.6

0.50, 0.70

0.45

0.36, 0.68

Urine CCA
No

93

70

60, 70

0.59

0.52, 0.62

0.3

0.30,0.40

0.35

0.31, 0.36

Yes

8

65

0, 80

0.6

− 0.13, 0.62

0.35

0.20, 1.0

0.33

0.31, 0.78

Anemia grade (gm/dl)
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Table 2 (continued)
n

EQ-VAS

Median

95% CI

EQ-5D index

EQ-VAS derived
disability weights

EQ-5D index
derived disability
weights

Median

Median

Median

95% CI

95% CI

95% CI

< 6.5

20

50

40, 70

0.6

0.29, 0.64

0.5

0.30, 0.60

0.40

0.36, 0.71

6.5–7.9

12

50

31, 69

0.56

0.47, 0.55

0.5

0.31, 0.69

0.44

0.35, 0.53

8.0–9.4

15

60

50, 80

0.65

0.60, 0.70

0.4

0.20, 0.50

0.35

0.31, 0.40

9.5–10.9

16

65

55, 80

0.72

0.62, 0.79

0.35

0.20, 0.45

0.28

0.21, 0.38

≥ 11.0

38

75

70, 80

0.7

0.69, 0.70

0.25

0.20, 0.30

0.31

0.30, 0.31

No

94

60

50, 70

0.65

0.62, 0.70

0.4

0.30, 0.50

0.35

0.31, 0.38

Yes

7

80

70, 87

0.7

0.65, 0.79

0.2

0.13, 0.30

0.31

0.21, 0.35

Hepatitis B surface antigen positive

UGIB-upper gastrointestinal bleeding, 95CI – 95% confidence intervals

Table 3 Spearman’s rank correlation coefficients of EQ-5 domains, EQ-VAS, EQ-5D index and derived disability weights
Mobility

Mobility

1

Self-care

0.3916*

Self-care

Usual
activities,

Pain and
discomfort

Anxiety and EQ-VAS
depression

0.4725*

1

Pain/discomfort

0.4721*

0.3898*

0.4550*

1

Anxiety/
depression

0.3364*

0.3429*

0.2253

0.3151*

1

EQ-VAS

− 0.6308* − 0.4928* − 0.6051*

− 0.4300*

− 0.4162*

1

0.4300*

− 0.7553* − 0.7494* − 0.7160*

EQ-VAS disabil- 0.6308*
ity weight

0.4928*

0.6051*

EQ-5D disability weight

0.7494*

0.7160*

0.7553*

EQ-5D Index
derived
disability
weights

1

Usual activities, 0.5849*

EQ-5D index

EQ-5D index EQ-VAS
derived
disability
weights

− 0.6270*
0.6270*

− 0.5922*

0.7288*

1

0.4162*

−1

− 0.7288*

0.5922*

− 0.7288* − 1

1
0.7288*

1

# Correlation coefficient

Interpretation of effect size

.90 to 1.00

Nearly, practically, or almost: perfect, distinct, infinite

.70 to .90

Very large, very high, huge

.50 to .70

Large, high, major

.30 to .50

Moderate, medium

.10 to .30

Small, low, minor

.00 to .10

Trivial, very small, insubstantial, tiny, practically zero

*

Significance level p < 0.05

Current care guides recommend endoscopy for all with
upper gastrointestinal bleeding and/or propranolol for
those with upper gastrointestinal bleeding and varices
[4, 42, 43].
Evaluation of EQ-5D primary data showed that our
participants reported more problems in all the five
measured health domains (mobility, self-care, usual
activities, pain/discomfort, and anxiety/depression)

than the study by Nascent et al. In addition, the mean
and median EQ-VAS scores in our study were also
lower than the study by Nascent et al. [34]. These differences were greatest for the domains of welfare, and
anxiety/depression This could be explained by dissimilarities in disease severity and access to better health
care services.
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Table 4 Summarizes the average marginal effects for EQ-VAS
derived disability weights and EQ-5D derived disability weights
by different covariates after linear regression and marginal
analysis
Delta-method
dy/dx

95%
Confidence
Intervals

p value

Model 1—EQ-VAS derived disability weights
Acute upper gastrointestinal bleeding

0.30

0.23, 0.37

0.001

Praziquantel

0.15

0.07, 0.22

0.001

Age range by decade

0.05

0.02, 0.07

0.001

Body Mass Index ≤ 18.5

0.05

− 0.05, 0.14

Female gender

Jaundice

0.07
− 0.12

Model 2—EQ-5D derived disability weights
Body mass index ≤ 18.5

Acute upper gastrointestinal bleeding

0.00002, 0.13

0.326
0.050

− 0.20, − 0.04 0.004

0.19

0.05, 0.33

0.009

0.10

0.02, 0.18

0.018

Ascites

0.19

0.05, 0.32

0.010

Age range by decade

0.03

0.003, 0.06

0.031

Female gender

0.10

0.03, 0.18

0.006

Praziquantel

0.12

0.04, 0.20

0.003

0.07

− 0.005, 0.14

0.069

Farmers
World Health Organization Anemia
grade

− 0.007 − 0.04, 0.03

Fig. 2 Average marginal effects for different covariate on EQ-VAS
derived disability weights

0.690

Marginal analysis enables examination of the impact of variable x (covariates) on
outcome y (disability weights) for representative cases

Jia et al. reported similar findings for dimensions of
pain/discomfort, anxiety/ depression, and mobility. However, differences are apparent for dimensions of usual
activities and self-care. The high prevalence of ascites
from that Jia et al. could explain this variance [32].
Our EQ-5D measurements (index and VAS) are comparable with a systematic review about health state estimates about diseases [44]. From our study, the EQ-5D
index and EQ-5D VAS were strongly positively correlated. This indicates that using Zimbabwe cross talk values did not adversely impact our EQ-5D index estimates.
The average disability weights EQ-5D VAS derived disability weights, and EQ-5D index derived disability
weights from our study population were 0.3 and 0.34
respectively. This suggests that our participants experienced poor health 4 months out of 12 months for each
survived life year. The “Global Burden of Disease Study
2017” has reported disability weights for hematemesis,
severe anemia, and ascites from schistosomiasis as 0.325,
0.149, and 0.144 respectively [35]. Nearly all our patients
reported a history of hematemesis. The average EQ-5D
VAS derived disability weights, and EQ-5D index derived
disability weights from our study population were 0.3
and 0.34 respectively. These are like what are reported by

Fig. 3 Average marginal effects for different covariate on EQ-5D
index derived disability weights

the “Global Burden of Disease Study 2017”. On the other
hand, disability weights for severe anemia, and ascites
from the “Global Burden of Disease Study 2017” are 3
to 4 times less than what we found from our study. The
“Global Burden of Disease Study 2017” did not provide
disability weights for acute variceal upper gastrointestinal
bleeding [35]. The implications of some of these findings
have been discussed by Jia et al. [32]. We echo similar
views.
Factors associated with EQ-5D VAS derived disability weights included acute upper gastrointestinal bleeding, Praziquantel drug treatment, age range by decade,
and female gender. While factors associated with EQ-5D
index derived disability weights included underweight
(BMI ≤ 18.5), acute upper gastrointestinal bleeding,
ascites, age range by decade, female gender, and Praziquantel drug treatment. Jia et al., reported that EQ-5D
VAS derived disability weights were associated with age,

Opio et al. J Patient Rep Outcomes

(2021) 5:112

impaired work capacity, depression, anxiety, ascites, and
active hepatitis B infection. We found similar findings for,
depression/anxiety, ascites, and active hepatitis B infection (Additional file 1). The negative coefficient in the
model could be explained by the inadvertent exclusion of
patients with hepatitis B virus decompensated liver disease i.e., jaundice, Additional file 1.
To the best of our knowledge, no study has directly
linked the occurrence of acute upper gastrointestinal
bleeding and schistosomiasis to higher disability. What
is known is that acute upper gastrointestinal bleeding
is the main reason for hospitalization and death among
patients with schistosomiasis due to S. mansoni [5, 6, 45,
46]. It therefore stands to reason that preventing acute
upper gastrointestinal bleeding could decrease health
loss in this population [8]. In the same way, addressing ascites and praziquantel adverse drug effects in this
population could also decrease health loss. These assertions are supported by published research which shows
that many acute illnesses requiring hospitalization are
usually associated with increased disability. Preventing
hospitalization decreases disability or health loss [47].
Acute upper gastrointestinal bleeding can be prevented
through secondary prophylaxis with drugs, bands, and
shunts. Ascites can be treated/prevented with drugs and
paracentesis.
Praziquantel treatment has been associated with
adverse drug effects including occurrence recurrent and
acute upper gastrointestinal bleeding in this population
[48, 49]. Mitigating these adverse effects could improve
health related quality of life measurements in this study
population.
One retrospective case series reported a significantly
higher proportion of females presented with upper gastrointestinal bleeding due to varices than males (39.4%
vs. 23.6%, p < 0.001) [50]. Research from this study population showed that female gender was a predictor of
recurrent upper gastrointestinal bleeding [7]. We propose that there is a link between female gender, recurrent
upper gastrointestinal bleeding, and disability. Nascent
et al., reported that median EQ-5D index values from
their study was significantly lower among females and
patients with comorbidities [34]. Underweight (body
mass index ≤ 18.5) has been associated with poor selfrated health [51].
Our study has limitations. Our sample size is small, and
this was a single Centre cross sectional study at a rural
primary health care facility. This makes our results less
conclusive for several reasons. Small studies are likely
to overestimate the magnitude of association. Furthermore, we could have inadvertently excluded individuals
in this community that do not have access to this facility for any reason including death due to acute upper
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gastrointestinal bleeding. This is evident from the direction of association between jaundice and disability.
We also acknowledge that our use of the EQ-5D (a
generic quality of life measurement tool) and the lack
of population-specific crosstalk data from the Albert
Nile basin could have made our EQ-5D index-disability
measurements less precise. The EQ-5D index could have
introduced an exogenous source of variance. Nevertheless, we found many similarities between our study and
what has been published by others about health related
quality of life measurements from patients with hepatic
schistosomiasis [32, 34, 35, 52]. This suggests that our
results might be more robust than we demonstrate.

Conclusions
Adult patients with upper gastrointestinal bleeding and
hepatic schistosomiasis from this rural primary health
facility in sub–Saharan Africa experienced poor health
and substantial health loss. These findings are comparable with studies from china and brazil about hepatic
schistosomiasis. We also identified several factors associated with individual health loss among participants
with upper gastrointestinal bleeding and schistosomiasis. These factors probably represent unmet health needs
and may point out potential areas for health intervention. Even so, more research is needed to confirm these
findings.
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